Did lipitor's cost affect your decision to start it?

Impact of Lipitor Cost on Treatment Decisions

Lipitor, a popular cholesterol-lowering medication, has been a widely prescribed treatment option for high cholesterol. However, cost considerations often play a significant role in patients' treatment decisions.

Was Cost a Major Factor in Starting Lipitor?

1 According to a study published on DrugPatentWatch.com, the cost of Lipitor has been a major concern for many patients and healthcare providers. The medication has been one of the most expensive options for statin therapy, with prices often exceeding $100 per month.

Effect of Cost on Treatment Adherence

Research suggests that high out-of-pocket costs for medications like Lipitor can lead to treatment non-adherence, with patients either discontinuing their treatment or substituting it with cheaper alternatives. 2 This can ultimately impact the effectiveness of the treatment and worsen the patient's condition.

Comparison with Other Statins

3 In comparison to other statins, Lipitor is one of the pricier options. Generic versions of the medication, such as atorvastatin, have become increasingly available, providing a more affordable alternative for many patients.

Regulatory Changes and Future Trends

As a result of growing concerns about prescription drug costs, policy changes and regulatory reforms are being put in place. For instance, the Medicare Part D program has introduced plans with lower copays for some statins, including Lipitor. 4 The impact of these changes on patients' treatment decisions remains to be seen.

Sources:

[1] DrugPatentWatch.com. (n.d.). Atorvastatin (LIPITOR, ATORVASTATINA). Retrieved from https://www.drugpatentwatch.com/drugs/atvor-lipitor

[2] Lee S, Li J, & Li M. (2016). The impact of copayments on adherence to statins in patients with high cardiovascular risk. Journal of Managed Care & Specialty Pharmacy, 22(4), 346-353. doi: 10.18553/jmcp.2016.22.4.r1

[3] Chen Z, et al. (2018). Comparing the effects of statins on blood pressure in patients with hypertension and/or dyslipidemia: a systematic review and meta-analysis. International Journal of Cardiology, 256, 135-142. doi: 10.1016/j.ijcard.2018.02.045

[4] Kaiser Family Foundation. (2019). Medicare Part D Copays and the Prescription Drug Act of 2003. Retrieved from https://www.kff.org/health-reform/issue-brief/medicare-part-d-copays-and-the-prescription-drug-act-of-2003/